Literature DB >> 27340761

Successful long-term (22 year) treatment of limited scleroderma using therapeutic plasma exchange: Is blood rheology the key?

Edward S Harris1, Herbert J Meiselman2, Patrick M Moriarty3, John Weiss4.   

Abstract

While a number of studies have shown short-term beneficial effects of therapeutic plasma exchange (TPE) for treating systemic scleroderma (SSc), there have been no reports on the very long-term usage of TPE as the sole systemic treatment intervention. We report the case of a male patient, originally diagnosed with limited systemic scleroderma (lcSSc) in early 1990, who has been undergoing regular plasmapheresis treatments for more than 22 years, beginning in late 1993. Prior to commencing treatment, the patient exhibited symptoms including severe gastro esophageal reflux disease (GERD) with esophagitis, frequent Raynaud's attacks, reduced lung function, and chronic chilling. With the exception of mild residual Raynaud's, all of the patient's symptoms reversed after three years of regular TPE treatments and he remains in complete remission. While the typical explanation for the therapeutic benefits seen with TPE focuses on temporary reduction of circulating antibodies or other pathogenic factors, we propose instead an explanation based on abnormal blood rheology as a novel disease pathogenesis model for SSc.

Entities:  

Keywords:  CREST syndrome; Limited scleroderma; blood viscosity; plasma exchange; plasmapheresis

Mesh:

Year:  2017        PMID: 27340761     DOI: 10.3233/CH-16140

Source DB:  PubMed          Journal:  Clin Hemorheol Microcirc        ISSN: 1386-0291            Impact factor:   2.375


  2 in total

Review 1.  Therapeutic plasma exchange for the treatment of systemic sclerosis: A comprehensive review and analysis.

Authors:  Edward S Harris; Herbert J Meiselman; Patrick M Moriarty; Allan Metzger; Miroslav Malkovsky
Journal:  J Scleroderma Relat Disord       Date:  2018-03-09

2.  Rheopheresis for Digital Ulcers and Raynaud's Phenomenon in Systemic Sclerosis Refractory to Conventional Treatments.

Authors:  Peter Korsten; Gerhard A Müller; Jan-Gerd Rademacher; Michael Zeisberg; Björn Tampe
Journal:  Front Med (Lausanne)       Date:  2019-09-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.